Return to Work of Lymphoma Survivors After Autologous Stem Cell Transplantation: A Single-Center Cross-Sectional Study




Autologous stem cell transplantation


How to Cite

Yıldız, J., Dal, M. S., Çakar, M. K., Yiğenoğlu, T. N., Merdin, A., İskender, D., Baysal, N. A., Batgi, H., Şahin, D., Bakırtaş, M., Darçın, T., Başçı, S., Ulu, B. U., & Altuntaş, F. (2021). Return to Work of Lymphoma Survivors After Autologous Stem Cell Transplantation: A Single-Center Cross-Sectional Study . Iranian Red Crescent Medical Journal, 23(7). (Original work published August 3, 2021)


Background: The effectiveness of autologous stem cell transplantation (ASCT) in patients with relapsed/refractory lymphoma is accepted by all authors. After ASCT, the 5-year overall survival rates can reach up to 80%. However, returning to work after ASCT and the employment status of these patients are unknown.

Objectives: This study aimed to examine the rate of not returning to work in the post-treatment period and the factors that may affect the employment status of patients who underwent ASCT with the diagnosis of relapsed/refractory lymphoma.

Methods: This cross-sectional study was conducted from January to June 2020. It was performed on patients within the age ranges of 18-65 who had undergone ASCT with the diagnosis of relapsed or refractory lymphoma and were in remission without recurrence one year after ASCT.

Results: In total, 80 (74.8%) out of 107 patients included in the study were male, and the median age was 49.0 (21-63). Majority of participants were primary school graduates (n=66, 61.7%) and married (n=90, 84.1%). Before ASCT, 30 (28.0%) patients worked in the private sector and 17 (15.9%) of them were self-employed. The median follow-up time was 34.8 months (12.4 - 124.7 months). During this follow-up period, 35 (57.3%) out of 61 patients did not return to work. Most of these patients had retired (n=29, 47.5%). It was observed that having a higher education level (OR: 0.32 [0.14-1.22] 95% CI, p:0.041) and being a public employee (OR: 0.30 (0.12-0.97) 95% CI, p:0.033) are independent factors that reduce the risk of not returning to work.

Conclusion: It was found that more than half of the patients did not return to work. The low level of education and employment in non-public sectors posed the risk of not returning to work. It may be possible for patients to return to work with well-planned options, such as part-time shifts.


  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30. doi: 10.3322/caac.21590. [PubMed: 31912902].
  2. Zahid U, Akbar F, Amaraneni A, Husnain M, Chan O, Riaz IB, et al. A review of autologous stem cell transplantation in lymphoma. Curr Hematol Malig Rep. 2017;12(3):217-26. doi: 10.1007/s11899-017-0382-1. [PubMed: 28478586].
  3. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002; 359(9323):2065-71. doi: 10.1016/S0140-6736(02)08938-9. [PubMed: 12086759].
  4. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540-5. doi: 10.1056/NEJM199512073332305. [PubMed: 7477169].
  5. Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 2013; 369(18):1681-90. doi: 10.1056/NEJMoa1301077. [PubMed: 24171516].
  6. Falzetti F, Di Ianni M, Ballanti S, Iodice G, Reale A, Minelli O, et al. High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk non-Hodgkin lymphoma. Clin Exp Med. 2012;12(3):165-71. doi: 10.1007/s10238-011-0157-2. [PubMed: 21928053].
  7. Naughton MJ, Weaver KE. Physical and mental health among cancer survivors: considerations for long-term care and quality of life. N C Med J. 2014;75(4):283-6. doi: 10.18043/ncm.75.4.283. [PubMed: 25046097].
  8. Yıldız F, Alaguney ME. Is early-stage breast cancer a risk for marital-dissolution? Med Sci Discov. 2020;7(7):566-9. doi: 10.36472/msd.v7i7.400.
  9. Schmidt ME, Scherer S, Wiskemann J, Steindorf K. Return to work after breast cancer: The role of treatment-related side effects and potential impact on quality of life. Eur J Cancer Care (Engl). 2019;28(4):e13051. doi: 10.1111/ecc.13051. [PubMed: 31033073].
  10. Johnsson A, Fornander T, Rutqvist LE, Olsson M. Work status and life changes in the first year after breast cancer diagnosis. Work. 2010;38(4):337-46. doi: 10.3233/WOR-2011-1137. [PubMed: 21508523]
  11. Yıldız F, Alaguney ME. Factors associated with the employment status of breast cancer survivors: a single center cross-sectional study. Int J Community Med Public Health. 2020;7(8):2874-9. doi: 10.18203/2394-6040.ijcmph20203357.
  12. Kiserud CE, Fagerli UM, Smeland KB, Fluge Ø, Bersvendsen H, Kvaløy S, et al. Pattern of employment and associated factors in long-term lymphoma survivors 10 years after high-dose chemotherapy with autologous stem cell transplantation. Acta Oncol. 2016;55(5):547-53. doi: 10.3109/0284186X.2015. 1125015. [PubMed: 27123741].
  13. Majhail NS. Long-term complications after hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther. 2017; 10(4):220-7. doi: 10.1016/j.hemonc.2017.05.009. [PubMed: 28641097].
  14. Pidala J, Anasetti C, Jim H. Health-related quality of life following haematopoietic cell transplantation: patient education, evaluation and intervention. BR J Haematol. 2010;148(3):373-85. doi: 10.1111/j.1365-2141.2009.07992.x. [PubMed: 19919651].
  15. Pidala J, Anasetti C, Jim H. Quality of life after allogeneic hematopoietic cell transplantation. Blood. 2009;114(1):7-19. doi: 10.1182/blood-2008-10-182592. [PubMed: 19336756].
  16. Syrjala KL, Langer SL, Abrams JR, Storer B, Sanders JE, Flowers ME, et al. Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma. JAMA. 2004; 291(19):2335-43. doi: 10.1001/jama.291.19.2335. [PubMed: 15150205].
  17. Hensel M, Egerer G, Schneeweiss A, Goldschmidt H, Ho AD. Quality of life and rehabilitation in social and professional life after autologous stem cell transplantation 7. Ann Oncol. 2002;13(2):209-17. doi: 10.1093/annonc/mdf031.
  18. Horsboel TA, Nielsen CV, Nielsen B, Jensen C, Andersen NT, de Thurah A. Type of hematological malignancy is crucial for the return to work prognosis: a register-based cohort study 4. J Cancer Surviv. 2013;7(4):614-23. doi: 10.1007/s11764-013-0300-z. [PubMed: 23949119].
  19. Abrahamsen AF, Loge JH, Hannisdal E, Holte H, Kvaløy S. Socio-medical situation for long-term survivors of Hodgkin's disease: a survey of 459 patients treated at one institution. Eur J Cancer. 1998;34(12):1865-70. doi: 10.1016/s0959-8049(98)00269-x. [PubMed: 10023307].
  20. Winterling J, Johansson E, Wennman-Larsen A, Petersson LM, Ljungman P, Alexanderson K. Occupational status among adult survivors following allo-SCT. Bone Marrow Transplant. 2014;49(6):836-42. doi: 10.1038/bmt.2014.26. [PubMed: 24614841].
  21. Kirchhoff AC, Leisenring W, Syrjala KL. Prospective predictors of return to work in the 5 years after hematopoietic cell transplantation. J Cancer Surviv. 2010;4(1):33-44. doi: 10.1007/s11764-009-0105-2. [PubMed: 19936935].
  22. Mosher CE, Redd WH, Rini CM, Burkhalter JE, Du Hamel KN. Physical, psychological, and social sequelae following hematopoietic stem cell transplantation: a review of the literature. Psychooncology. 2009;18(2):113-27. doi: 10.1002/ pon.1399. [PubMed: 18677717].